CN1041203C - 吡唑并吡啶化合物的制备方法 - Google Patents

吡唑并吡啶化合物的制备方法 Download PDF

Info

Publication number
CN1041203C
CN1041203C CN92103372A CN92103372A CN1041203C CN 1041203 C CN1041203 C CN 1041203C CN 92103372 A CN92103372 A CN 92103372A CN 92103372 A CN92103372 A CN 92103372A CN 1041203 C CN1041203 C CN 1041203C
Authority
CN
China
Prior art keywords
compound
low
alkyl
salt
carboxyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN92103372A
Other languages
English (en)
Chinese (zh)
Other versions
CN1067427A (zh
Inventor
盐川洋一
赤羽厚
片山博仁
光长孝文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of CN1067427A publication Critical patent/CN1067427A/zh
Application granted granted Critical
Publication of CN1041203C publication Critical patent/CN1041203C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Developing Agents For Electrophotography (AREA)
CN92103372A 1991-04-10 1992-04-09 吡唑并吡啶化合物的制备方法 Expired - Lifetime CN1041203C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9107513.5 1991-04-10
GB919107513A GB9107513D0 (en) 1991-04-10 1991-04-10 Pyrazolopyridine compound and processes for preparation thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNB971253781A Division CN100508975C (zh) 1991-04-10 1992-04-09 吡唑并吡啶化合物的用途

Publications (2)

Publication Number Publication Date
CN1067427A CN1067427A (zh) 1992-12-30
CN1041203C true CN1041203C (zh) 1998-12-16

Family

ID=10692949

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB971253781A Expired - Lifetime CN100508975C (zh) 1991-04-10 1992-04-09 吡唑并吡啶化合物的用途
CN92103372A Expired - Lifetime CN1041203C (zh) 1991-04-10 1992-04-09 吡唑并吡啶化合物的制备方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CNB971253781A Expired - Lifetime CN100508975C (zh) 1991-04-10 1992-04-09 吡唑并吡啶化合物的用途

Country Status (23)

Country Link
US (1) US5234930A (enExample)
EP (1) EP0516941B1 (enExample)
JP (2) JP2546470B2 (enExample)
KR (1) KR100248700B1 (enExample)
CN (2) CN100508975C (enExample)
AT (1) ATE146473T1 (enExample)
AU (1) AU653007B2 (enExample)
CA (1) CA2065644C (enExample)
DE (1) DE69215965T2 (enExample)
DK (1) DK0516941T3 (enExample)
ES (1) ES2095976T3 (enExample)
FI (1) FI100969B (enExample)
GB (1) GB9107513D0 (enExample)
GR (1) GR3022113T3 (enExample)
HU (2) HU214871B (enExample)
IE (1) IE921086A1 (enExample)
IL (1) IL101544A (enExample)
MX (1) MX9201672A (enExample)
NO (1) NO300271B1 (enExample)
RU (1) RU2069662C1 (enExample)
SG (1) SG43917A1 (enExample)
TW (1) TW205550B (enExample)
UA (1) UA27252C2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541213A (en) * 1993-06-24 1996-07-30 Eisai Co., Ltd. Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
EP0737193A1 (en) * 1993-12-29 1996-10-16 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine adenosine antagonists
WO1997040047A1 (en) * 1996-04-25 1997-10-30 Fujisawa Pharmaceutical Co., Ltd. Preventives and remedies for ischemic intestinal lesion and ileus
AUPO111096A0 (en) * 1996-07-18 1996-08-08 Fujisawa Pharmaceutical Co., Ltd. New compound
EP0972525A4 (en) * 1997-03-18 2000-11-29 Fujisawa Pharmaceutical Co PREVENTIVE AND HEALING AGENTS AGAINST HYPERPHOSPHATEMIA
SE9801526D0 (sv) * 1998-04-29 1998-04-29 Astra Ab New compounds
EP1084710B1 (en) * 1998-06-01 2006-10-18 Astellas Pharma Inc. Adenosine a1 antagonists for male sterility
US20040152659A1 (en) * 1999-05-12 2004-08-05 Fujisawa Pharmaceutical Co. Ltd. Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
AU2002239348A1 (en) * 2000-12-15 2002-06-24 Glaxo Group Limited Pyrazolopyridine derivatives
ATE301653T1 (de) * 2000-12-15 2005-08-15 Glaxo Group Ltd Pyrazolopyridine
DE60201074T2 (de) * 2001-03-08 2005-09-15 Smithkline Beecham Corp. Pyrazolopyridinderivate
JP2004525150A (ja) * 2001-03-30 2004-08-19 スミスクライン ビーチャム コーポレーション 治療用化合物としてのピラゾロピリジン類の使用
WO2002078700A1 (en) 2001-03-30 2002-10-10 Smithkline Beecham Corporation Pyralopyridines, process for their preparation and use as therapteutic compounds
ATE332301T1 (de) * 2001-04-10 2006-07-15 Smithkline Beecham Corp Antivirale pyrazolopyridin verbindungen
EP1385847B1 (en) * 2001-04-27 2005-06-01 SmithKline Beecham Corporation Pyrazolo[1,5-a]pyridine derivatives
AUPR548601A0 (en) * 2001-06-06 2001-06-28 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyrazinecompound and pharmaceutical use thereof
PL366827A1 (en) * 2001-06-21 2005-02-07 Smithkline Beecham Corporation Imidazo[1,2-a]pyridine derivatives for the prophylaxis and treatment of herpes viral infections
DE60220525T2 (de) * 2001-09-07 2008-02-07 Smithkline Beecham Corp. Pyrazolo-pyridine für die behandlung von herpes-ansteckungen
ATE326466T1 (de) * 2001-10-05 2006-06-15 Smithkline Beecham Corp Imidazopyridinderivate zur verwendung bei der behandlung von herpes-vireninfektion
ES2292839T3 (es) * 2001-12-11 2008-03-16 Smithkline Beecham Corporation Derivados de pirazolo-piridina como agentes contra el herpes.
JP2006504728A (ja) * 2002-10-03 2006-02-09 スミスクライン ビーチャム コーポレーション ピラソロピリジン誘導体系治療用化合物
BRPI0712381A2 (pt) * 2006-06-06 2012-07-10 Avigen Inc compostos de pirazolo[1,5-a]piridina substituìda e seus métodos de uso
US9572528B1 (en) 2012-08-06 2017-02-21 Los Angeles Biomedical Research Insitute at Harbor-UCLA Medical Center Monitor for SIDS research and prevention

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0299209A2 (en) * 1987-06-15 1989-01-18 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and processes for preparation thereof
EP0379979A1 (en) * 1989-01-23 1990-08-01 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compounds and processes for preparation thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0299209A2 (en) * 1987-06-15 1989-01-18 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and processes for preparation thereof
EP0379979A1 (en) * 1989-01-23 1990-08-01 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compounds and processes for preparation thereof

Also Published As

Publication number Publication date
AU1398892A (en) 1992-10-15
AU653007B2 (en) 1994-09-15
TW205550B (enExample) 1993-05-11
NO921413D0 (no) 1992-04-09
KR100248700B1 (ko) 2000-08-01
FI100969B (fi) 1998-03-31
RU2069662C1 (ru) 1996-11-27
EP0516941A1 (en) 1992-12-09
IL101544A (en) 1996-06-18
UA27252C2 (uk) 2000-08-15
GR3022113T3 (en) 1997-03-31
IL101544A0 (en) 1992-12-30
US5234930A (en) 1993-08-10
FI921522A0 (fi) 1992-04-07
DK0516941T3 (da) 1997-01-06
MX9201672A (es) 1992-10-01
DE69215965T2 (de) 1997-04-10
CN1067427A (zh) 1992-12-30
CN100508975C (zh) 2009-07-08
JP2903040B2 (ja) 1999-06-07
FI921522L (fi) 1992-10-11
CN1205205A (zh) 1999-01-20
EP0516941B1 (en) 1996-12-18
DE69215965D1 (de) 1997-01-30
HU211680A9 (en) 1995-12-28
HU214871B (hu) 1998-07-28
JP2546470B2 (ja) 1996-10-23
JPH08208650A (ja) 1996-08-13
JPH05112566A (ja) 1993-05-07
NO300271B1 (no) 1997-05-05
IE921086A1 (en) 1992-10-21
CA2065644A1 (en) 1992-10-11
HUT61300A (en) 1992-12-28
HU9201213D0 (en) 1992-07-28
ATE146473T1 (de) 1997-01-15
SG43917A1 (en) 1997-11-14
KR920019787A (ko) 1992-11-20
CA2065644C (en) 2002-12-03
GB9107513D0 (en) 1991-05-29
NO921413L (no) 1992-10-12
ES2095976T3 (es) 1997-03-01

Similar Documents

Publication Publication Date Title
CN1041203C (zh) 吡唑并吡啶化合物的制备方法
CN1187367C (zh) 具有麻醉剂活性的3α－羟基－3β－甲氧基甲基－21－杂环取代的类固醇
CN1105708C (zh) 1－苯基吡唑化合物类及其药学应用
CN1527814A (zh) 氧化氮合酶抑制剂磷酸盐
JPH08176145A (ja) アロイル−ピペリジン誘導体
CN1639164A (zh) 含氮杂环化合物
CN1129941A (zh) 取代的氮杂二氢亚吲哚基化合物及其制备方法
CN1100773C (zh) 苯并呋喃羧酸胺和磺酰胺
CN1289481C (zh) 作为降低脂质剂的联苯甲酰胺化合物
CN1325380A (zh) 苯衍生物和它们的药物用途
CN1176080C (zh) 茚并一,萘并一和苯并环庚二氢噻唑衍生物,它们的制备以及它们作为降低食欲药的用途
JP2000063363A (ja) 新規なトリアゾール誘導体
CN1440399A (zh) 具comt抑制活性的香豆素衍生物
CN1170814C (zh) 用于强化胆碱能活性的酰胺化合物
JPH07500604A (ja) 高血圧治療用エチルアラニンアミノジオール化合物
CN1251571A (zh) 2－苯氧基苯胺类衍生物
CN1098841C (zh) 新颖的酰胺衍生物及其医药组合物
CN1152026C (zh) 多环的2-氨基二氢噻唑体系、它们的制备方法和它们作为药物的用途
CN1041589A (zh) 含n-杂环化合物的保心剂和局部缺血疾病治疗剂以及化合物的制备方法
CN1125444A (zh) 新型的二氮杂萘衍生物，它们的制备方法和含有它们的尤其用作抗增生药的药物组合物
CN1141292C (zh) 细胞生长抑制剂
CN1132204A (zh) 新的杂环酰胺
CN1346347A (zh) 环胺衍生物和它们的用途
CN1746171A (zh) 杂环并嘧啶酮衍生物、制备方法和用途
CN1112109A (zh) 新型芳基甘氨酰胺衍生物及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C15 Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993)
OR01 Other related matters
ASS Succession or assignment of patent right

Owner name: ASTELLAS PHARMA INC.

Free format text: FORMER OWNER: FUJISAWA PHARMACEUTICAL CO., LTD.

Effective date: 20060407

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20060407

Address after: Tokyo, Japan

Patentee after: Yamanouchi Pharma Co., Ltd.

Address before: Osaka Japan

Patentee before: Fujisawa Pharmaceutical Co., Ltd.

C17 Cessation of patent right
CX01 Expiry of patent term

Expiration termination date: 20120409

Granted publication date: 19981216